CLXT - CLXT STOCK NEWS

Calyxt (NASDAQ:CLXT), a plant-based technology company, will host its First Quarter 2021 Financial Results Conference Call on May 6, 2021, at 4:30 p.m. Eastern Time. The call will include a discussion of the financial results for the first quarter ended March 31, 2021, followed by a question-and-answer session. The conference call can be accessed via toll-free and international dial-in numbers, and it will be available for replay afterwards. Calyxt aims to revolutionize plant usage through its proprietary TALEN® gene editing technology.

Calyxt (NASDAQ:CLXT) reported a revenue increase of 270% year-over-year, reaching $13.9 million in Q4 2020, attributed to grain sales. The net loss for Q4 was $13.4 million, slightly higher than Q4 2019. The company secured a commitment from ADM for its remaining 2020 grain production and executed a licensing agreement with S&W Seed Company for its alfalfa product. Calyxt's cash position improved to $30 million, including a $14 million capital raise. Its go-to-market strategies focus on seed sales, trait development, and licensing, positioning it for growth across multiple agricultural markets.

Calyxt (NASDAQ:CLXT), a plant-based technology company, announced its participation in several investor conferences in March 2021. The events include:

• Bank of America Securities Global Agriculture & Materials Virtual Conference on March 3, featuring a gene editing panel presentation by Co-Founder Dan Voytas.
• Virtual 33rd Annual ROTH Conference on March 16, with 1x1 meetings led by CFO Bill Koschak.
• Investor Summit: Q1 Virtual Summit from March 23-25, with presentations also by Koschak.

Investors can arrange meetings through their conference representatives or contact Calyxt directly.

Calyxt (NASDAQ:CLXT) has appointed industry experts to its Scientific Advisory Board, chaired by co-founder Dan Voytas, Ph.D. This initiative aims to identify high-value plant-derived products using Calyxt's proprietary innovation platform. The board will focus on various sectors, including therapeutics and cosmetics, seeking both immediate and long-term opportunities. In a related statement, Voytas emphasized the transformative role of gene editing in creating complex metabolites for enhanced benefits, while executive chairman Yves Ribeill highlighted the potential of this expertise to drive innovation.

Calyxt (NASDAQ:CLXT) has entered into a non-exclusive seed distribution agreement with Perdue AgriBusiness, marking a significant step in its revised business model. This agreement will enable Perdue to directly contract with farmers for the production of high-oleic soybeans, starting from the 2021 planting season. This is the first seed sale agreement for Calyxt, reflecting its strategy to leverage its plant breeding technology and focus on R&D. The collaboration aims to meet increasing demand for high-oleic products in the food industry.

Calyxt, Inc. (NASDAQ:CLXT) announced the appointment of Dr. Yves Ribeill as Executive Chair of the Board effective immediately. This follows the departure of Jim Blome, the former CEO, who is leaving for other opportunities. Dr. Ribeill, with extensive experience in biotechnology, will assist in the search for a new CEO. The board expressed gratitude to Blome for his role in streamlining Calyxt’s business model and positioning the company for future growth through innovative plant-based solutions. Calyxt focuses on plant gene editing technology and aims for significant innovations beyond traditional agriculture.

Calyxt, Inc. (NASDAQ: CLXT) announced a conference call scheduled for Thursday, March 4, 2021, at 4:30 p.m. EST to discuss its financial results for the fourth quarter and full year ended December 31, 2020. CEO Jim Blome and CFO Bill Koschak will lead the call, followed by a Q&A session. Investors can access the call via toll-free numbers or through the company's investor relations webpage. A replay will be available for one month post-call.

Calyxt, a plant-based technology company, has secured a contract with ADM to sell its entire 2020 grain production of high oleic soybean, marking a significant step in its market strategy. This agreement encompasses approximately four million bushels, with sales commencing in Q3 2020 and extending through late 2021. The high oleic soybean was recognized as the first commercially approved gene-edited food in the U.S. The partnership allows Calyxt to allocate resources towards licensing its technology and developing new products.

Calyxt, Inc. (NASDAQ: CLXT) has announced a research collaboration with NRGene to utilize their cloud-based genomics platform. This partnership aims to enhance Calyxt's trait discovery and breeding processes across various crops, particularly hemp. By adopting NRGene's QuickGENETICS™ and CannaGene™ technologies, Calyxt plans to integrate advanced data analytics and AI to optimize product performance. The collaboration is expected to expedite the identification of critical gene targets, positioning Calyxt to lead in the hemp market.